Novartis registers new Phase IIIb IgAN trial and VEXAS Phase 2; gMG trial still active

Novartis had registry activity across seven studies the week of September 28, 2026, spanning new trial registrations, continuing Phase 2 and Phase 3 programs, and observational analyses.

• A new Phase IIIb trial pairs zigakibart with atrasentan against zigakibart plus placebo in adults with primary IgA nephropathy, called "LUMINA IgAN." The study is not yet recruiting, with an estimated start of 2026-12-01 and an estimated enrollment of 340 participants¹.
• Arumakimig (MAS825), a Phase 2 therapy for VEXAS syndrome, is recruiting in a 52-week placebo-controlled trial. The study has an estimated enrollment of 120 participants and evaluates whether patients achieve improvement of key VEXAS manifestations along with oral glucocorticoid reduction at Week 52².
• Remibrutinib (LOU064), a Phase 3 trial in generalized myasthenia gravis called "RELIEVE," remains active but not recruiting. The study evaluates efficacy, safety and tolerability of remibrutinib versus placebo in adult patients with generalized myasthenia gravis on stable standard-of-care treatment³, with approximately 180 eligible participants randomized in a ratio of 1:1 to receive either remibrutinib or matching placebo³.
• YTB323, a Phase 1/2 CAR-T therapy studied in severe, refractory systemic lupus erythematosus, is listed as completed, with enrollment of 21 participants⁴.
• A retrospective observational study in Spain is tracking clinical experience with iptacopan in adult C3G patients treated through an early access program, called "ROUTE-C3G." The study is recruiting, with an estimated enrollment of 35 participants⁵.
• An observational study is examining real-world disease modifying therapy use in women with multiple sclerosis around pregnancy, using a pooled closed claims database containing closed payer medical and pharmacy claims data for patients in the United States⁶, with an estimated enrollment of 2607 participants⁶.
• A completed external control arm study compared survival outcomes for 177Lu-PSMA-617 against a switch in androgen receptor pathway inhibitor therapy in metastatic castration-resistant prostate cancer, with enrollment of 1525 participants⁷.